Single- and multiple-dose bioequivalence of two once-daily tramadol formulations using stereospecific analysis of tramadol and its demethylated (M1 and M5) metabolites

Current Medical Research and Opinion

Volumn 23, Issue 7, 2007, Pages 1593-1604

  Eradiri, Okponanabofa ^a   Sista, Suryanarayana ^a   Lai, John C K ^a   Nguyen, Oanh H ^a   Silverstone, Peter H ^b  

^a Biovail Technologies Ltd   (United States)

^b Biovail Corporation   (Canada)

Author keywords

Bioavailability; Bioequivalence; Chirality; Enantiomers; Pharmacokinetics; Tramadol

Indexed keywords

DRUG METABOLITE; TRAMADOL; TRAMADOLOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMETHYLATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; DYSPEPSIA; ENANTIOMER; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NAUSEA AND VOMITING; NORMAL HUMAN; SINGLE DRUG DOSE; STEADY STATE; STEREOSPECIFICITY;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; STEREOISOMERISM; THERAPEUTIC EQUIVALENCY; TRAMADOL;

EID: 34547196422     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X199781     Document Type: Article

References (33)

1. Desmeules JA, Piguet V, Collart L, Dayer P. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol 1996;41:7-12
2. Raffa RB, Friderichs E, Reimann W, et al. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther 1993;267:331-40
3. Gillen C, Haurand M, Kobelt DJ, Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol 2000;362:116-21
4. Frankus E, Friderichs E, Kim SM, Osterloh G. On separation of isomeres, structural elucidation and pharmacological characterization of 1-(m-methoxyphenyl)-2-(dimethylaminomethyl)-cyclohexan-1-ol. Arzneimittelforschung 1978;28:114-21
5. Lintz W, Erlacin S, Frankus E, Uragg H. Biotransformation of tramadol in man and animal. Arzneimittelforschung 1981;31:1932-43
6. Lintz W, Barth H, Osterloh G, Schmidt-Bothelt E. Bioavailability of enteral tramadol formulations. 1st communication: capsules. Arzneimittelforschung 1986;36:1278-83
7. Wu WN, McKown LA, Liao S. Metabolism of the analgesic drug ULTRAM* (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites. Xenobiotica 2002;32:411-25
8. Paar WD, Frankus P, Dengler HJ. The metabolism of tramadol by human liver microsomes. Clin Invest 1992; 70:708-10
9. Quetglas EG, Azanza JR, Cardenas E, et al. Stereoselective pharmacokinetic analysis of tramadol and its main phase I metabolites in healthy subjects after intravenous and oral administration of racemic tramadol. Biopharm Drug Dispos 2006;28:19-33
10. Pedersen RS, Damkier P, Brosen K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol 2006; 62:513-21
11. Liu HC, Liu TJ, Yang YY, Hou YN. Pharmacokinetics of enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in human subjects. Acta Pharmacol Sin 2001;22:91-6
12. Valle M, Garrido MJ, Pa von JM, et al. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O-desmethyltramadol, in rats. J Pharmacol Exp Ther 2000;293:646-53
13. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004;43:879-923
14. Babul N, Noveck R, Chipman H, et al. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage 2004;28:59-71
15. Hair PI, Curran MP, Keam SJ. Tramadol extended-release tablets. Drugs 2006;66:2017-27
16. Data on file. Biovail Study No. 2551 (B01-567PK-TRAP03). A two-way, crossover, open-label, fasting, single-dose and multiple-dose bioavailability study of tramadol hydrochloride extended-release 200 mg tablets (once-daily) versus Ultram (50 mg tablets four times daily) in normal healthy non-smoking male and female subjects. Biovail Corporation. Chantilly, VA.
17. Gana TJ, Pascual ML, Fleming RR, et al. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin 2006;22:1391-401
18. Adler L, McDonald C, O'Brien C, Wilson M. A comparison of once-daily tramadol with normal release tramadol in the treatment of pain in osteoarthritis. J Rheumatol 2002;29:2196-9
19. Bodalia B, McDonald CJ, Smith KJ, et al. A comparison of the pharmacokinetics, clinical efficacy, and tolerability of once-daily tramadol tablets with normal release tramadol capsules. J Pain Symptom Manage 2003;25:142-9
20. Mehvar R, Jamali F. Bioequivalence of chiral drugs: stereospecific versus non-stereospecific methods. Clin Pharmacokinet 1997;33:122-41
21. Karim A. Enantioselective assays in comparative bioavailability studies of racemic drug formulations: nice to know or need to know? J Clin Pharmacol 1996;36:490-9
22. Mehvar R, Elliott K, Parasrampuria R, Eradiri O. Stereospecific high-performance liquid chromatographic analysis of tramadol and its O-demethylated (M1) and N,O-demethylated (M5) metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007; in press
23. Diletti E, Hauschke D, Steinij ans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 1991;29:1-8
24. Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 1992;30(Suppl 1):S51-8
25. Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World Health Organization study in primary care. JAMA 1998;280:147-51
26. Katz WA. Pharmacology and clinical experience with tramadol in osteoarthritis. Drugs 1996;52(Suppl 3):39-47
27. Roth SH. Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol 1998;25:1358-63
28. Grond S, Meuser T, Uragg H, et al. Serum concentrations of tramadol enantiomers during patient-controlled analgesia. Br J Clin Pharmacol 1999;48:254-7
29. Laugesen S, Enggaard TP, Pedersen RS, et al. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005;77:312-23
30. Malonne H, Sonet B, Streel B, et al. Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol. Br J Clin Pharmacol 2004;57:270-8
31. Hernandez-Lopez C, Martinez-Farnos L, Karhu D, et al. Comparative bioavailability between two tramadol once-daily oral formulations. Methods Find Exp Clin Pharmacol 2006;28:373-8
32. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996;60:636-44
33. Pedersen RS, Damkier P, Brosen K. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: A population study. Clin Pharmacol Ther 2005;77:458-67